Testing a New NMDA Receptor Antagonist Added to Antipsychotic Treatment
for Adults With Borderline Personality Disorder
in a 12-Week Randomized Double-Blind Study
Led by The Alfred · Updated on 2025-08-15
150
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Borderline Personality Disorder BPD is a common and serious psychiatric condition that affects millions worldwide, leading to significant difficulties in daily life and high rates of suicidal thoughts and actions. Young women are especially at risk, with BPD being diagnosed three times more often in women than men. The causes of BPD are complex, involving both biological and environmental factors such as abuse and family issues, which contribute to emotional and behavioral challenges. Currently, no medications are specifically approved to treat BPD effectively, and many patients struggle with existing treatments due to side effects or lack of response.
Researchers are evaluating a novel drug that blocks a brain receptor called NMDA, which has been approved for Alzheimers disease and is being studied for other psychiatric conditions. In this trial, 150 adults with BPD will be randomly assigned to receive either the study drug at a dose of 20 mg daily or a placebo, in addition to their current antipsychotic treatment, for 12 weeks. The trial is double-blind, meaning neither participants nor researchers know who receives the drug or placebo, to fairly assess the drugs effects.
Participants will be closely monitored throughout the study with regular assessments of their borderline symptoms and cognitive function using specific rating scales at multiple time points over 12 weeks. Safety and tolerability will also be observed. This thorough evaluation aims to determine whether adding this novel drug can improve symptoms and functioning in people living with BPD during and at the end of the treatment period.
CONDITIONS
Brief Title
A Novel Drug for Borderline Personality Disorder
Research Team
J
Jayashri Kulkarni AM, MBBS,MPM,FRANZCP,PhD
A
Anthony deCastella, DipAppSci,BA,MA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Current diagnosis of Borderline Personality Disorder or a score of 8 or higher on the Diagnostic Interview for Borderline patients or a score of 15 or higher on the Zanarini Rating Scale for Borderline Personality Disorder
Able to read and write English proficiently
You will not qualify if you...
Acute delirium or severe head injury
Epilepsy, seizure disorder, history of seizures (excluding febrile convulsions), or risk factors for epilepsy
Significant liver, kidney, blood, or heart disease
Current use of NMDA antagonists, L-dopa, dopamine agonists, or anticholinergic drugs
Lifetime diagnosis of schizophrenia, schizoaffective disorder, substance-induced psychotic disorder, or bipolar I disorder
Suicide risk requiring inpatient admission as assessed by psychiatrist
Taking more than 4 psychotropic medications
Planned changes to psychotropic medication or psychotherapy during study
Substance abuse or dependence requiring treatment in the last 3 months
Pregnant, breastfeeding, or not using appropriate contraception if of child-bearing age
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 12 weeks
Participants receive either the active drug or placebo daily for 12 weeks as part of the trial treatment.
Weekly visits for up to 12 weeks
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Testing a New NMDA Receptor Antagonist Added to Antipsychotic Treatment
for Adults With Borderline Personality Disorder
in a 12-Week Randomized Double-Blind Study
Testing Personalized vs Standardized Emotion Regulation Skills
for Improving Emotional Health and Reducing Negative Feelings
Study of One-Time Moderate or High-Intensity Cycling Effects on Stress and Brain Function in Adults with Borderline Personality Disorder
A Multi-center Randomized Study Comparing Amygdala fMRI Neurofeedback to Sham Feedback for Treating Emotional Instability in Borderline Personality Disorder
Evaluating Cognitive Reappraisal-by-Distancing Training to Improve Emotion Regulation in Borderline Personality Disorder Patients
Evaluating Compassion Focused Therapy to Reduce Internalized Stigma in Mental Disorders A Multi-center Randomized Controlled Study
Studying Relationship Addiction in Adults Aged 18 to 45 with Borderline Personality Disorder, Bipolar Disorder, or No Psychiatric Disorders
Study on the Effects of Physical Activity on the Sense of Self in Adults with Schizophrenia, Borderline Personality Disorder, or Vestibular Syndromes
Study of EMDR Psychotherapy for Adults with Borderline Personality Disorder to Improve Emotional and Behavioral Symptoms
Study of Dialectical Behavior Therapy on Emotional Processing and Self-Harm in Adults with Emotional Instability
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial.